University of Rochester
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Rochester sits in the top decile of US sponsors by registered trial count (#53 of 15,742 sponsors by registered trial count).
University of Rochester: 636 sponsored US clinical trials, 94 recruiting.
University of Rochester sponsors 636 registered US clinical trials on ClinicalTrials.gov, 94 of them currently recruiting, and 448 completed. 54 of these trials are in Phase 3-4 (later-stage) and 147 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer, with 7 trials.
Top-decile sponsor footprint
University of Rochester ranks in the top decile of sponsors by registered trial count (#53 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
448 of 506 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
636 total, page 7 of 13
Buspirone in Parkinson's Disease
NCT02803749
Cognitive Training for Older Caregivers
NCT03036423
Effect of Maternal Diabetes on Brain Development, as Measured by Neonatal Electroencephalogram (EEG)
NCT02968628
Effects of Mindfulness on PTSD
NCT03484390
Improving Well-Being for Older Adult Family Dementia Caregivers
NCT03881631
A Study of Transcutaneous Electrical Nerve Stimulation for Overactive Bladder
NCT02922842
The Effects of a 12 Week Home-based Exercise Intervention on Physical Performance in Patients With Cancers of the Gastrointestinal Tract With Pre- Cachexia or Cachexia
NCT04802486
Pilot Study on Energy Therapy or Massage to Reduce Fatigue
NCT02758756
Understanding Coagulation and Inflammation in Burns
NCT03077269
Suicide Prevention Training for PC Providers-in-training
NCT02996344
Pre-Habilitation Exercise Intervention
NCT02849717
Ceftriaxone and Jaundice in Neonates
NCT03133637
Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention
NCT02684344
Vision-based Speed of Processing Cognitive Training and Mild Cognitive Impairment
NCT02559063
Enzalutamide for Bladder Cancer Chemoprevention
NCT02605863
Aromatherapy for Chemotherapy-induced Symptoms
NCT02670941
NIR Fluorescence Imaging of Lymphatic Transport Using ICG
NCT02680067
Comparison of Three Licensed Influenza Vaccines
NCT03068949
Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial
NCT02456662
The Leaky Lung Test
NCT02306473
Influenza Immunity in Children
NCT02559505
URMC Related Haplo-identical Donor BMT
NCT02660281
Study of Calcium Metabolism in Teenage Girls With Type 1 Diabetes
NCT03156179
Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease
NCT02561702
Exercise Intervention for LGBT Cancer Survivors
NCT02459769
Chest Shielding in Premature Infants During Phototherapy
NCT02552927
Improving Communication About Patient Priorities in Multimorbidity
NCT02100982
Peer Led Asthma Self Management for Adolescents: PLASMA
NCT02293499
DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA
NCT02413749
Assessment of Prototype Hand-Held Fundus Camera
NCT01899222
Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients
NCT02413801
Regorafenib in Metastatic Colorectal Cancer
NCT02466009
Devel. and Eval. of an Active Surveillance Decision Aid for Men With Low or Intermediate Grade Prostate Cancer
NCT02342626
Social Connections and Late Life Suicide
NCT02188485
Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer
NCT02347618
Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy
NCT02164721
TTE and Dysphagia in Anterior Cervical Surgery
NCT02326116
Optical Coherence Tomography of Tear Film Dynamics In-Vivo
NCT02554084
Efficacy of Isradipine in Early Parkinson Disease
NCT02168842
Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities
NCT02240498
Investigation of Teacher-Mediated Toilet Training Using a Manualized Moisture Alarm Intervention
NCT02369445
Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
NCT02213107
Get Ready And Empowered About Treatment
NCT02165735
School-based Asthma Care for Teens (SB-ACT)
NCT02206061
Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy
NCT02247960
Multi-Colored Placido Disk Viability
NCT02148497
Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax
NCT02322528
Connect.Parkinson: Connecting Individuals With Parkinson Disease to Specialists in Their Homes
NCT02038959
High-dose Vitamin D Supplementation for ADT-induced Side Effects
NCT02064946
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients
NCT02109744
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 66 |
| Phase 2 | 81 |
| Phase 3 | 20 |
| Phase 4 | 34 |
Therapeutic Areas
What is open in the University of Rochester pipeline
94 recruiting of 636 indexed (15% open); 448 completed (70%).
Phase mix: 54 late (III/IV) vs 147 early (I/II) (early-phase heavy).
Top condition: Cancer (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Rochester: open-pipeline peers nationwide
Peers matched on 636 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Rochester sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 636 trials (± recruiting share)
- US Department of Veterans Affairs · 632 trials · 0% recruiting
- University of Southern California · 617 trials · 16% recruiting
- Baylor College of Medicine · 616 trials · 15% recruiting
- University of California, Davis · 657 trials · 19% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Loma Linda University · 15% recruiting · 237 trials
- Dompé Farmaceutici S.p.A · 15% recruiting · 27 trials
- Vanderbilt-Ingram Cancer Center · 15% recruiting · 189 trials
- Brown University · 15% recruiting · 231 trials
Related
What to do with this University of Rochester page
636 registered trials is a research-attention snapshot, not an endorsement of University of Rochester or any single study.
- 94 of University of Rochester's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cancer is the condition University of Rochester studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Rochester pipeline card: 636 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.